attach research report excerpt
research report written
entir broker partner auerbach
grayson auerbach grayson
auerbach grayson distributing/provid
research report consider
report solid result revenu ep come
estim consensu beat driven unexpect boost japan
respond favour reimburs chang outsid row sale
line us perform miss sale estim airsens product
cycl matur growth may revert industri pace see platform
refresh stronger expans non-sleep indic lift ep forecast
maintain hold rate revis price target per cdi
per share us common stock
report normalis ep estim
consensu strong revenu growth vs estim
driven unexpect japanes demand respond favour reimburs
chang gross margin line oper expens
aggreg oper cash flow beat vs estim
reflect tighter work capit manag beat oper
us revenu miss forecast reflect industri level growth
whilst offer stale year rel matur
lead us expect flow gener iter perhap within month
mask cycl appear durabl hope term
sustain double- digit categori growth face new near-term competit
respiron fph japan strong ahead reimburs chang
support remot telemonitor patient follow-up connect platform
enabl sleep physicians/provid drove strong adopt elsewher
european perform line forecast row sale
ahead forecast oper leverag outlook look strong
manag aspir keep oper expens growth low half revenu
growth outlook gross margin also posit geograph mix trend
back slightli toward row expect expand uptak vpap/astr
homecar set particularli manag copd patient
hold solid reflect oper leverag
report solid result revenu ep come
estim consensu beat driven
unexpect boost japan respond favour reimburs
chang outsid row sale line us perform
miss sale estim airsens product cycl matur
growth may revert industri pace see platform
refresh stronger expans non-sleep indic lift
ep forecast maintain hold rate revis price
target per cdi per share us common stock
snapshot report normalis ep
estim consensu strong revenu growth
vs estim driven unexpect japanes demand
respond favour reimburs chang gross margin
line oper expens aggreg oper cash flow
beat vs estim reflect tighter
work capit manag beat oper incom
confer call takeaway us revenu miss forecast
reflect industri level growth whilst offer
stale year rel matur lead us expect
appear durabl hope term sustain double-
digit categori growth face new near-term competit
respiron fph japan strong ahead reimburs chang
support remot telemonitor patient follow-up connect
platform enabl sleep physicians/provid drove strong
adopt elsewher european perform line forecast row
sale ahead forecast oper
leverag outlook look strong manag aspir keep oper
expens growth low half revenu growth outlook gross
margin also posit geograph mix trend back slightli toward row
expect expand uptak vpap/astr homecar set
particularli manag copd patient
model chang rais revenu
revenu base primarili higher sale row
busi continu revis forward sg expens
driver lower percentag net revenu connect care strategi lift
recur revenu exposur take cost chang increas
ep estim approxim
risk catalyst report
gross margin aud eur exposur patent infring suit
cycl gross margin improv option heart failur
copd chronic diseas manag
share issu
issu wilson advisori stockbrok limit abn australian financi servic licenc particip asx group
read conjunct disclosur disclaim report import disclosur regard compani subject report explan
recommend found end document
health equip suppli
profit loss
fund equiti
fund debt
fund cash
health equip suppli
resm inc develop manufactur sell posit air pressur pap devic treatment sleep disord breath recent
year compani diversifi pap offer market oral applianc ventil form respiratori support
report solid result revenu ep come estim consensu beat driven
unexpect boost japan respond favour reimburs chang outsid row sale line us perform
miss sale estim airsens product cycl matur growth may revert industri pace see platform
refresh lift ep forecast maintain hold rate revis price target per cdi per share us
intang goodwil
grow easier access diagnosi sleep disord
net debt averag
rel short product cycl refresh price point
new devic area
gross margin expos fx aud sgd vs usd
 sg typic net sale
product mix higher-end apap ventil bilevel mask
higher gross margin
competit intensifi low-end cpap market
restor sustain industri us devic volum flow
increment margin benefit mix shift apap
risk view
increas competit price point
slower-than-expect market growth particularli challeng
price reimburs challeng usa elsewher
relat poor complianc cpap
health equip suppli
disclaim disclosur
